Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:729 (7 April), doi:10.1136/bmj.39133.668681.BE (published 23 March 2007)
Andrew D Hopper, gastroenterology specialist registrar1, Simon S Cross, reader in pathology and honorary consultant in pathology3, David P Hurlstone, consultant gastroenterologist1, Mark E McAlindon, consultant gastroenterologist1, Alan J Lobo, consultant gastroenterologist1, Marios Hadjivassiliou, consultant neurologist4, Marion E Sloan, general practitioner5, Simon Dixon, senior lecturer in health economics2, David S Sanders, consultant gastroenterologist1
1 Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, 2 Health Economics and Decision Science (HEDS), University of Sheffield, Sheffield, 3 Section of Oncology and Pathology, Division of Genomic Medicine, University of Sheffield Medical School, Sheffield, 4 Department of Neurology, Royal Hallamshire Hospital, 5 Surgery, 29 Blackstock Road, Sheffield S14 1AB
Correspondence to: A D Hopper, 15 Nairn Street, Sheffield S10 1UL andydhopper{at}aol.com
Design An initial retrospective cohort of patients attending for gastroscopy was analysed to derive a clinical decision tool that could increase the detection of coeliac disease without performing routine duodenal biopsy. The tool incorporated serology (measuring antibodies to tissue transglutaminase) and stratifying patients according to their referral symptoms (patients were classified as having a "high risk" or "low risk" of coeliac disease). The decision tool was then tested on a second cohort of patients attending for gastroscopy. In the second cohort all patients had a routine duodenal biopsy and serology performed.
Setting Teaching hospital in Sheffield.
Participants 2000 consecutive adult patients referred for gastroscopy recruited prospectively.
Main outcome measure Evaluation of a clinical decision tool using patients' referral symptoms, tissue transglutaminase antibody results, and duodenal biopsy results.
Results No cases of coeliac disease were missed by the pre-endoscopy testing algorithm. The prevalence of coeliac disease in patients attending for endoscopy was 3.9% (77/2000, 95% confidence interval 3.1% to 4.8%). The prevalence in the high risk and low risk groups was 9.6% (71/739, 7.7% to 12.0%) and 0.5% (6/1261, 0.2% to 1.0%). The prevalence of coeliac disease in patients who were negative for tissue transglutaminase antibody was 0.4% (7/2000). The sensitivity, specificity, positive predictive value, and negative predictive value for a positive antibody result to diagnose coeliac disease was 90.9%, 90.9%, 28.6%, and 99.6%, respectively. Evaluation of the clinical decision tool gave a sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 60.8%, 9.3%, and 100%, respectively.
Conclusions Pre-endoscopy serological testing in combination with biopsy of high risk cases detected all cases of coeliac disease. The use of this decision tool may enable the endoscopist to target patients who need a duodenal biopsy.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+